Advanced or metastatic clear-cell renal cell carcinoma
1 paper
- Human trial1
Latest
The Lancet Oncology
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Randomised trial in 658 peopleKidney